Allergan plc AGN reported quarterly earnings of $5.22 per share on Monday, beating the analyst consensus estimate of $4.57 by 14.22%.
This is a 21.68% increase over earnings of $4.29 per share in the same period last year.
The company reported quarterly sales of $4.351 billion, beating the analyst consensus estimate of $4.09 billion by 6.38%. This is a 6.64% increase over sales of $4.08 billion the same period last year.
"I am proud of Allergan's colleagues who achieved many important milestones in 2019 that will make a difference to patients for years to come," CEO Brent Saunders said in a statement.
"They achieved FDA approval of Ubrelvy, a first-in-class oral treatment for migraine; two new approvals for Botox for pediatric spasticity; approval for Vraylar for bipolar depression; and filings for two new eye care drugs
Bimatoprost SR for glaucoma and Abicipar for Age-related Macular Degeneration."
Allergan shares were trading up slightly at $197.23 at the time of publication in Monday's premarket session. The stock has a 52-week high of $197 and a 52-week low of $114.27.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
